Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fowlpox-CEA-TRICOM vaccine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Fowlpox-CEA-TRICOM vaccine is a recombinant fowlpox-based vaccine designed to induce an immune response against cancer cells expressing carcinoembryonic antigen (CEA). The vaccine incorporates TRICOM, a combination of co-stimulatory molecules (B7-1, ICAM-1, LFA-3), intended to enhance T-cell activation and improve the anti-tumor immune response. It has been investigated in clinical trials for various advanced or metastatic cancers, often in combination with sargramostim (GM-CSF) or chemotherapy, to potentially increase the number of immune cells and make tumor cells more sensitive to the vaccine. The vaccine aims to stimulate CEA-specific T-cell immunity to target and kill tumor cells.
- Other names
- recombinant fowlpox-CEA(6D)/TRICOMfowlpox-CEA-TRICOM vaccineCEA/TRICOM-based vaccinerF-CEA(6D)/B7.1/ICAM-1/LFA-3
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ICAM1 (Intercellular Adhesion Molecule 1)CD58 (Leukocyte function-associated antigen 3)CD80 (T-lymphocyte activation antigen CD80)
Beyond the preview
Go deeper on fowlpox-CEA-TRICOM vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fowlpox-CEA-TRICOM vaccine.